Predictive value of EASIX for CKD patients with CRS Authors: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian Published: 2026 ABSTRACT This study aimed to investigate predictive value of endothelial activation and the endothelial activation and stress index (EASIX) for chronic kidney disease (CKD) patients with cardiorenal syndrome (CRS). A retrospective study was conducted on 253 CKD patients admitted to our hospital from January 2021 to June 2024. Patients were divided into CRS group (n = 77) and non-CRS group (n = 176). Univariate and binary Logistics regression analyses were performed to identify influencing factors. The receiver operating characteristic (ROC) curve was used to evaluate the predictive value of EASIX for CKD patients with CRS. There were significant differences in terms of hypertension, red blood cell count, red cell distribution width (RDW), blood urea nitrogen, albumin, interleukin-6, C-reactive protein, EASIX, and CKD stage between the 2 groups (P < .05). Binary Logistics regression analysis indicated that RDW, EASIX, and CKD stagings were independent influencing factors for CKD patients with CRS (P < .05). The predictive area under the curve (AUC) for EASIX was 0.821 with a standard error of 0.028 (95% confidence interval [CI]: 0.767–0.876), with a Youden index of 0.62, sensitivity of 85.71%, and specificity of 76.14%. The AUC for RDW was 0.742, with a standard error of 0.035 (95% CI: 0.674–0.811), Youden index of 0.48, sensitivity of 77.92%, and specificity of 69.32%. The AUC for CKD stage was 0.737, with a standard error of 0.032 (95% CI: 0.675–0.799), Youden index of 0.47, sensitivity of 92.21%, and specificity of 55.11%. Post-treatment patients with EASIX ≤ 3.18 had higher blood calcium levels and lower blood phosphorus levels compared to those with EASIX > 3.18, with significant differences (P < .05). EASIX demonstrates high predictive value in predicting CKD patients with CRS, suggesting its inclusion as an evaluation index. 1. Introduction Chronic kidney disease (CKD) has become a serious public health issue globally, with its prevalence showing an increasing trend year by year.[1] As the condition progresses, CKD patients often face the risk of various complications, among which cardiorenal syndrome (CRS) as a severe complication in the progression of CKD significantly increases the mortality and disability rates of patients.[2] CRS refers to a clinical syndrome where acute or chronic dysfunction of either the heart or kidneys triggers dysfunction in the other organ, with both organs mutually impacting and causing a vicious cycle, leading to complex disease conditions and increased treatment challenges.[3] Currently, there are still many challenges in the early identification and prediction of CRS. Although traditional clinical indicators have certain reference value, they have limitations in terms of sensitivity and specificity in predicting the development of CRS in CKD patients. Therefore, finding more precise and effective predictive indicators is crucial for improving the prognosis of CKD patients.[4] Endothelial cells, as barriers between blood and tissues, play a crucial role in maintaining vascular homeostasis, regulating inflammatory responses, and coagulation functions. Endothelial activation refers to the transition of endothelial cells from a resting state to an activated state after various stimuli, releasing a series of bioactive substances involved in inflammatory responses and vascular injury processes.[5] The stress index reflects the overall response capacity of the body to various stress states and is closely related to endothelial function. The endothelial activation and stress index (EASIX) is a novel biomarker for assessing endothelial function, calculated from indicators like serum lactate dehydrogenase, and has been proven by multiple studies to predict the prognosis of various diseases.[6,7] Based on this, this study aims to explore the predictive value of EASIX for CKD patients with CRS. It is hoped that this study can provide new biomarkers for the early identification of high-risk populations for CKD patients developing CRS, thereby facilitating timely intervention measures, improving patient prognosis, and reducing the incidence and mortality of CRS. 1.1. Research objects 253 CKD patients admitted to our hospital between January 2021 and June 2024 were retrospectively selected. Following the criteria outlined in previous research guidelines,[8,9] patients were categorized into a CRS group (n = 77) and a non-CRS group (n = 176) based on the occurrence of CRS. Inclusion criteria were as follows: all patients met the clinical diagnosis of CKD[10]; patients were aged 18 years or older; and complete clinical data were available. Exclusion criteria included: patients with malignant tumors or infections; patients with urinary tract infections or obstructions; and patients with concurrent blood or immune system disorders. 1.2. Research methods 1.2.1. General data collection Patient general information was collected using the electronic medical record system. 1.2.2. Laboratory indicator collection Fasting morning blood samples were collected upon admission for patients, and blood inflammatory biomarkers were detected using enzyme-linked immunosorbent assay kits (purchased from Kamaishu Shanghai Biotech). 1.2.3. EASIX calculation[11] EASIX = Lactate Dehydrogenase (LDH) (U/L) × Creatinine (Cr) (mg/dL)/ Platelet Count (PLT) (109/L). 1.3. Statistical analysis The experimental data collected were analyzed using SPSS 27.0 (International Business Machines Corporation, Armonk). The Shapiro–Wilk test was used for normality testing. For normally distributed continuous data, results were expressed as X¯±S, and comparisons were made using independent sample t-tests. Non-normally distributed data were represented using MQ2 (Q1, Q3), and calculations were performed using the Mann–Whitney U test. Categorical data were presented as frequencies or rates, and comparisons were conducted using χ2 test. Factors influencing the data were analyzed using univariate and binary Logistics regression analysis. The predictive value of EASIX for the development of CKD patients with CRS was evaluated using the receiver operating characteristic (ROC) curve analysis. A significance level of P < .05 was considered statistically significant for differences. Variables with statistical significance in univariate analysis and clinically relevant factors were included in the multivariate logistic regression model to adjust for potential confounders. 2. Results 2.1. Univariate analysis of factors influencing CKD patients with CRS A comparison of hypertension, red blood cell count, red cell distribution width (RDW), blood urea nitrogen, albumin, interleukin-6, C-reactive protein, EASIX, and CKD staging between the 2 groups of patients showed statistically significant differences (P < .05), as shown in Table 1. Table 1Univariate analysis of factors influencing CKD patients with CRS.IndicatorCRS group (n = 77)Non-CRS group (n = 176)Z/t/χ2 ValueP valueAge (yr)69.00 (53.00, 82.00)65.00 (54.00, 75.00)−1.224.221Gender Male481150.211.646 Female2961BMI (kg/m2)23.83 (22.36, 26.81)25.08 (22.25, 27.73)−1.168.243Heart rate (bpm)76.00 (69.00, 86.00)77.00 (71.00, 82.75)−0.573.567Hypertension Yes721474.590.032 No529Diabetes Yes31820.869.351 No4694Smoking Yes34621.813.178 No43114Alcohol drinking Yes18243.671.055 No59152WBC (×109/L)6.06 (5.24, 7.54)6.19 (5.26, 7.60)−0.282.778RBC (T/L)3.22 (2.81, 3.76)3.83 (3.34, 4.44)−5.285<.001RDW (fL)14.00 (12.85, 15.70)12.15 (11.13, 13.20)−6.132<.001BUN (mg/dL)19.00 (14.65, 25.40)10.15 (6.83, 19.33)−6.390<.001ALB (g/L)33.80 (29.40, 36.65)36.85 (33.95, 39.70)−4.650<.001IL-6 (pg/mL)12.45 (6.63, 26.80)6.40 (3.45, 13.75)−3.690<.001CRP (μg/mL)6.45 (3.03, 16.05)4.30 (1.20, 11.05)−2.119<.001EASIX6.66 (4.34, 11.30)1.47 (0.93, 3.06)−8.133<.001CKD diagnostic staging 2–369749.695<.001 4–57179ALB = albumin, BMI = body mass index, BUN = blood urea nitrogen, CRP = C-reactive protein, EASIX = endothelial activation and stress index, IL-6 = interleukin-6, RBC = red blood cell, RDW = red cell distribution width, WBC = white blood cell. Univariate analysis of factors influencing CKD patients with CRS. ALB = albumin, BMI = body mass index, BUN = blood urea nitrogen, CRP = C-reactive protein, EASIX = endothelial activation and stress index, IL-6 = interleukin-6, RBC = red blood cell, RDW = red cell distribution width, WBC = white blood cell. 2.2. Binary logistics regression analysis of factors influencing CKD patients with CRS Using significant variables identified in the univariate analysis as independent variables and assigning values accordingly [with continuous variables maintaining their original values and categorical variables coded as follows: CKD staging (2–3 = 0, 4–5 = 1); hypertension (No = 0, Yes = 1)], an analysis was conducted with CRS as the dependent variable (CRS = 1, Non-CRS = 0). The results of the binary Logistics regression analysis indicated that RDW, EASIX, and CKD staging were independent factors influencing the development of CRS in CKD patients (P < .05), as shown in Table 2. Table 2Binary logistics regression analysis of factors influencing CKD patients with CRS.FactorβStandard errorWald P Exp(β)95% CIHypertension−0.5911.1520.263.6080.5540.058–5.299RBC0.1030.3480.087.7681.1080.560–2.193RDW0.2730.0899.373.0021.3141.103–1.564BUN−0.0220.0290.566.4520.9780.924–1.036ALB−0.0570.0431.757.1850.9450.868–1.028IL-6−0.0020.0180.009.9230.9980.963–1.034CRP0.0000.0150.002.9610.9990.970–1.029EASIX0.1010.0504.038.0441.1061.002–1.220CKD staging2.2670.71510.049.0029.6542.376–39.221Constant−4.4162.2883.723.0540.012–ALB = albumin, BUN = blood urea nitrogen, CI = confidence interval, CKD = chronic kidney disease, CRP = C-reactive protein, CRS = cardiorenal syndrome, EASIX = endothelial activation and stress index, IL-6 = interleukin-6, RBC = red blood cell count, RDW = red cell distribution width. Binary logistics regression analysis of factors influencing CKD patients with CRS. ALB = albumin, BUN = blood urea nitrogen, CI = confidence interval, CKD = chronic kidney disease, CRP = C-reactive protein, CRS = cardiorenal syndrome, EASIX = endothelial activation and stress index, IL-6 = interleukin-6, RBC = red blood cell count, RDW = red cell distribution width. 2.3. ROC curve analysis of predictive value of indicators The ROC analysis results indicated that EASIX had a good predictive area under the curve (AUC) of 0.821, with a standard error of 0.028 (95% confidence interval [CI]: 0.767–0.876) and a Youden index of 0.62. At this threshold, the sensitivity was 85.71% and specificity was 76.14%. For RDW, the predictive AUC was 0.742, with a standard error of 0.035 (95% CI: 0.674–0.811) and a Youden index of 0.48. The sensitivity and specificity at this point were 77.92% and 69.32%, respectively. CKD staging showed a predictive AUC of 0.737, with a standard error of 0.032 (95% CI: 0.675–0.799) and a Youden index of 0.47. The sensitivity and specificity were 92.21% and 55.11%, respectively. See Table 3 and Figure 1 for details. Table 3ROC analysis results.IndicatorAUCSE95% CIIYoudenSensitivitySpecificityP valueeOptimal cut-off valueRDW0.7420.0350.674–0.8110.4877.9269.32<.00112.75EASIX0.8210.0280.767–0.8760.6285.7176.14<.0013.18CKD staging0.7370.0320.675–0.7990.4792.2155.11<.001–AUC = area under the curve, CI = confidence interval, CKD = chronic kidney disease, ELISA = enzyme-linked immunosorbent assay, RDW = red cell distribution width, ROC = receiver operating characteristic, SE = standard error. ROC analysis results. AUC = area under the curve, CI = confidence interval, CKD = chronic kidney disease, ELISA = enzyme-linked immunosorbent assay, RDW = red cell distribution width, ROC = receiver operating characteristic, SE = standard error. ROC curve. ROC = receiver operating characteristic. 2.4. Mineral levels before and after treatment in patients with different EASIX values Patients in the EASIX ≤ 3.18 group showed higher blood calcium levels and lower blood phosphorus levels after treatment compared to the EASIX > 3.18 group, with statistically significant differences (P < .05). See Table 4 for details. Table 4Mineral levels before and after treatment in patients with different EASIX values.Count caseBlood calcium (mmol/L)Blood phosphorus (mmol/L)EASIX ≤ 3.181452.27 ± 0.181.26 ± 0.24EASIX > 3.181082.11 ± 0.281.75 ± 0.58t value5.5209.177P value<.001<.001ELISA = enzyme-linked immunosorbent assay. Mineral levels before and after treatment in patients with different EASIX values. ELISA = enzyme-linked immunosorbent assay. 3. Discussion CKD is a common chronic condition with high incidence and mortality rates. CRS, a common complication of CKD, refers to a clinical syndrome where the heart and kidneys mutually influence each other in pathophysiological processes, leading to deterioration in the function of one or both organs. The occurrence and progression of CRS not only increase the complexity of patient treatment but also significantly elevate the risk of mortality. Therefore, identifying an effective predictive indicator to early recognize the risk of CKD patients developing CRS holds crucial clinical significance. EASIX, as a novel biomarker, has shown promising prospects in predicting the prognosis of various diseases in recent years. This study aimed to explore the predictive value of EASIX for CKD patients with CRS. Endothelial cells are a major component of the vascular wall with various physiological functions, including regulating vascular tone, maintaining vascular barrier integrity, and modulating the entry of immune cells and circulating inflammatory mediators. In CKD patients, due to impaired renal function leading to the accumulation of metabolic waste products and toxins in the body, as well as the combined effects of oxidative stress, inflammatory reactions, among other factors, endothelial cells are susceptible to damage and activation. Upon activation, endothelial cells release a series of inflammatory mediators and cytokines such as tumor necrosis factor-α, which further exacerbate damage to the kidneys and heart, forming a vicious cycle that ultimately results in the occurrence and progression of CRS.[11,12] This study demonstrates that RDW is also an independent influencing factor for CKD patients with CRS, aligning with the aforementioned observations. EASIX is a composite index calculated from 3 indicators: LDH, creatinine, and platelet count, all of which are closely related to endothelial cell activation and damage.[13] LDH is an enzyme widely present in cells of various tissues in the human body, released into the bloodstream when cells are damaged or die. In CKD patients, LDH levels often rise due to endothelial cell activation and damage, serving as an indirect marker of endothelial cell damage. Creatinine, a byproduct of muscle metabolism, is primarily excreted by the kidneys. Previous studies by Fang Y et al[14] have also suggested an association between LDH and renal injury patients, aligning with the findings of this study. In CKD patients, decreased creatinine excretion due to renal impairment leads to elevated blood creatinine levels. Research by Leite AM et al[15] has shown that blood creatinine has predictive value in the prognosis of CRS, consistent with the results of this study, indicating that elevated creatinine levels not only reflect renal damage but may also be associated with further deterioration of renal function due to endothelial dysfunction. Endothelial dysfunction can affect renal blood perfusion and filtration, exacerbating creatinine accumulation.[16] Platelets play a crucial role in the clotting process. In CKD patients, due to endothelial cell activation and damage, platelets are easily activated and aggregate at sites of injury, promoting thrombus formation that further exacerbates renal and cardiac ischemia and damage.[17,18] Therefore, changes in platelet count can also reflect the degree of endothelial cell activation and damage. EASIX, by integrating LDH, creatinine, and platelet count, comprehensively reflects the status of endothelial cell activation and damage. When endothelial cells are activated and damaged, LDH levels rise, creatinine levels increase, and platelet count becomes abnormal, all leading to an elevated EASIX value. Therefore, an elevated EASIX value can serve as an early warning signal of increased risk of CRS in CKD patients. Previous studies by Gu JS et al[19] have also demonstrated the predictive value of elevated EASIX in the prognosis of kidney-related surgeries, consistent with the findings of this study. The results of this study demonstrate that EASIX has a high AUC value in predicting the development of CRS in CKD patients, with an AUC of 0.821 and a standard error of 0.028 (95% CI: 0.767–0.876). This indicates that EASIX can effectively differentiate between high-risk and low-risk individuals for developing CRS among CKD patients. By identifying high-risk patients early, physicians can promptly intervene by enhancing renal function monitoring, adjusting treatment plans, controlling blood pressure, and managing blood glucose levels to reduce the risk of CRS occurrence. The predictive value of EASIX not only lies in the early identification of high-risk patients but also provides guidance for clinical decision-making. For instance, for patients with elevated EASIX values, physicians can closely monitor changes in their renal and cardiac function and adjust treatment plans promptly. Additionally, EASIX can serve as an indicator to evaluate treatment effectiveness. A decrease in EASIX values post-treatment suggests treatment efficacy, while a sustained or elevated EASIX value may prompt the consideration of modifying treatment plans or implementing more aggressive interventions. Furthermore, this study discovered that the incidence of complications in the EASIX ≤ 3.18 group was lower than in the EASIX > 3.18 group. Additionally, after treatment, blood calcium levels were higher in the EASIX ≤ 3.18 group and blood phosphorus levels were lower compared to the EASIX > 3.18 group. These results indicate a close association between EASIX values and the prognosis of CKD patients. Blood calcium is closely linked to bone health and mineral metabolism, crucial for the normal functioning of the body. Proper control of blood phosphorus is equally important for CKD patients, as elevated levels may trigger a series of complications. The findings suggest that patients with higher EASIX values tend to have a poorer prognosis, necessitating more proactive treatment and care. Based on EASIX values, clinicians can implement more aggressive treatment and care measures for patients with a poorer prognosis, such as intensified monitoring of the condition and adjustment of treatment plans, to enhance patient outcomes and improve their quality of life. Therefore, this further underscores the potential of EASIX as an important indicator for evaluating the prognosis of CKD patients. Although EASIX demonstrates promising prospects in predicting the development of CRS in CKD patients, its predictive value still has certain limitations. Firstly, the calculation of EASIX involves multiple indicators, and the measurement of these indicators may be influenced by various factors such as differences in laboratory testing methods and individual patient variations. Despite adjustment for several clinical variables, residual confounding cannot be completely excluded due to the retrospective design. Factors such as medication use, nutritional status, and other comorbidities were not fully captured and may influence the observed associations. Additionally, this study has certain limitations. On one hand, it is a single-center study, and the relatively homogeneous sample source may not fully represent the overall situation of CKD patients across different regions and medical settings, potentially limiting the generalizability of the research findings. On the other hand, the retrospective design of the study relies on historical medical records for data collection, which may lead to incomplete or inaccurate information recording. It is also challenging to precisely control and adjust for some potential confounding factors, which could impact the rigor of the study conclusions. Subsequent researches involving multicenter, prospective studies are necessary to further validate and refine these findings. As this was a single-center retrospective study with a relatively limited sample size, selection bias and regional differences may affect the generalizability of the findings. Future multicenter prospective studies with larger cohorts are needed to further validate the predictive value of EASIX in CKD patients with CRS. Although ROC curve analysis demonstrated good predictive performance of EASIX, internal validation methods such as bootstrapping or cross-validation were not performed due to the retrospective design and sample size limitations. Future studies should incorporate both internal and external validation to enhance model robustness. 4. Conclusion In conclusion, EASIX, as a novel biomarker, demonstrates promising prospects in predicting the development of CRS in CKD patients. Its predictive principle is primarily based on the relationship between endothelial cell activation and CRS, as well as the association between the components of EASIX and endothelial cell activation. By early identification of high-risk patients, guiding clinical decisions, and evaluating prognosis, EASIX can provide essential reference points for the treatment and management of CKD patients. However, the predictive value of EASIX still has certain limitations that require further research and optimization. Future endeavors may involve optimizing the calculation method of EASIX, conducting multicenter studies with large sample sizes, delving deeper into the predictive mechanisms of EASIX, and exploring its application in clinical treatments, which aims to enhance the accuracy and reliability of EASIX predictions. Author contributions Conceptualization: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Data curation: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Formal analysis: Duo Zhao, Fengxiao Zhang, Haitao Tian. Funding acquisition: Haitao Tian. Investigation: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Methodology: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Software: Fengxiao Zhang. Supervision: Duo Zhao, Fengxiao Zhang, Hongyan Wang. Validation: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Visualization: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian. Writing – original draft: Duo Zhao, Fengxiao Zhang, Hongyan Wang. Writing – review & editing: Duo Zhao, Fengxiao Zhang, Hongyan Wang, Haitao Tian.